SNY » Topics » Project highlights

This excerpt taken from the SNY 20-F filed Mar 4, 2009.

Project Highlights

 

Our main compounds currently in clinical development Phase IIb or III are described in the paragraphs below.

 

Life Cycle Management (LCM) development programs for our marketed pharmaceutical products are described above in “— Pharmaceutical Products”.

 

This excerpt taken from the SNY 20-F filed Mar 7, 2008.

Project Highlights

 

Our main compounds currently in clinical development Phase IIb or III are described in the paragraphs below.

 

Life Cycle Management (LCM) development programs for our top 15 pharmaceutical products are described above in “— Principal Pharmaceutical Products”.

 

As in any dynamic portfolio, some projects are stopped, while other candidates enter into development. The following programs were halted in 2007:

 

   

In the Central Nervous System area: xaliproden (SR57746) in Alzheimer disease indication only, paliroden (SR57667) in Alzheimer and Parkinson disease indications, and dianicline (SSR591813) which was indicated for smoking cessation;

 

   

In the Internal Medecine area: icatibant (HOE140) for the treatment of osteoarthritis pain.

 

This excerpt taken from the SNY 20-F filed Apr 3, 2007.

Project highlights

 

Life Cycle Management (LCM) development programs for our top 15 pharmaceutical products are described above in “— Principal Pharmaceutical Products”.

 

This excerpt taken from the SNY 20-F filed Mar 31, 2006.

Project Highlights

 

Life cycle management development programs for our marketed products are described above under “Major Products.”

 

This excerpt taken from the SNY 20-F filed Apr 11, 2005.

Project highlights

 

LCM development programs for our marketed products are described above in the “–Products–Pharmaceutical Activity”.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki